Institutional Investors Adjust Stakes in Royalty Pharma During Third Quarter
What happened
During the third quarter, Cooper Investors PTY Ltd. reduced its position in Royalty Pharma by 69.3%. Conversely, NorthCrest Asset Management LLC grew its stake by 41.3%, and Wedmont Private Capital increased its holdings by 17.8%. Other firms, including Legacy Wealth Asset Management LLC and Congress Asset Management Co., also acquired new stakes in the biopharmaceutical company.
From dailypolitical.com
Why it matters
The transactions reflect changing investment positions among major institutional holders of Royalty Pharma. These changes are documented in the company's required filings with the Securities and Exchange Commission.
From dailypolitical.com
Who's involved
- Royalty PharmaBiopharmaceutical company whose shares were subject to institutional trading.
- Pablo LegorretaFounder and CEO of Royalty Pharma.
- Securities and Exchange CommissionGovernment agency that requires formal regulatory filing of ownership changes.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Royalty PharmaSpeculative
Royalty Pharma might face market price pressure due to institutional selling and insider activity.
Keep exploring
The entities involved
-
Royalty Pharma
biopharmaceutical company based in New York City
Nothing else this week.